Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only
Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only
£85.00
Ships today if ordered and paid by 12 PM EST. (Except Saturdays & Sundays)
Due to our rigorous quality control standards and the fragile nature of our products, we cannot accept returns. In the rare occasion that your order arrives with missing, incorrect or damaged items, please email info@britishpeptides.co.uk for assistance. Our customer support representatives are standing by to ensure that our customers are 100% satisfied with our product quality, customer support and delivery. Cancellations must be requested by email before the order shipment has shipped. Once the order has shipped you may not cancel your order. Please contact us at info@britishpeptides.co.uk with any questions or concerns that you may have regarding your order. We will do our absolute best to assist you as quickly and satisfactorily as possible.Thank you.
Price range: £40.00 through £490.00
£15.00
Price range: £40.00 through £175.00
The name Wolverine Blend is a reference used within the research peptide community, drawn from the fictional Marvel character known for his accelerated regenerative biology. In laboratory literature, BPC-157 and TB-500 are among the most studied peptides in the context of cellular repair signalling and tissue remodelling mechanisms in preclinical models — making the combination a recognised pairing in regenerative biology research. The name is used for identification purposes only and does not constitute a therapeutic claim. This product is supplied strictly for in vitro and preclinical laboratory research use and is not intended for human or veterinary use.
What Is the Wolverine Blend?
The Wolverine Blend is a research-grade lyophilised formulation combining two well-characterised synthetic peptides — BPC-157 (Body Protection Compound 157) and TB-500 (Thymosin Beta-4 fragment) — at 10mg each, yielding 20mg total per vial. The blend is designed for controlled laboratory environments where researchers require a dual-peptide system to examine combined receptor interactions, intracellular signalling cascades, and peptide stability under experimental conditions.
Both peptides have independently established mechanistic profiles in preclinical literature, and their combination enables researchers to study potential pathway crosstalk and additive molecular behaviour in a single, precisely formulated reagent.
This product is intended exclusively for in vitro laboratory and preclinical research use. It is not approved for, nor intended for, human or veterinary administration, consumption, or therapeutic application of any kind.
BPC-157 (Body Protection Compound 157)
TB-500 (Thymosin Beta-4 fragment)
Blend specification
Mechanism of Action in Laboratory Studies
In preclinical and in vitro research contexts, each peptide engages distinct molecular targets:
BPC-157 has been studied for its interaction with growth factor receptor pathways, including VEGFR and EGFR signalling cascades, modulation of nitric oxide synthesis in vascular endothelial cell lines, and FAK/paxillin pathway activity in fibroblast migration assays.
TB-500 (the active domain of Thymosin Beta-4) is studied for its role in actin sequestration dynamics, regulation of G-actin/F-actin ratios in cytoskeletal research, and downstream effects on cell migration and proliferation signalling in controlled in vitro systems.
Together, this dual-peptide formulation allows researchers to examine whether concurrent receptor engagement across these distinct pathways produces additive or independent signalling behaviour in shared experimental models — an area of active mechanistic investigation in preclinical molecular biology.
Research Applications
The Wolverine Blend is used in regulated laboratory environments for:
Dual-pathway receptor signalling studies Examination of simultaneous BPC-157 and TB-500 receptor interactions in cell-based assay systems, with focus on independent versus convergent downstream signalling outputs.
Cytoskeletal dynamics research TB-500’s actin-sequestering domain provides a mechanistic tool for studying G-actin/F-actin equilibrium and cytoskeletal reorganisation in fibroblast and endothelial cell lines.
Angiogenic signalling pathway analysis BPC-157’s interaction with VEGF-mediated pathways enables investigation of angiogenic receptor activity and vascular signalling dynamics in in vitro vascular models.
Multi-peptide stability and formulation research Study of co-formulated peptide stability, structural integrity under storage conditions, and compatibility in lyophilised dual-component systems.
Preclinical molecular biology and pharmacokinetic modelling Both peptides are used in preclinical models examining receptor binding kinetics, peptide half-life, and signalling persistence across biological matrices.
Product Specifications
| Parameter | Detail |
|---|---|
| Product name | Wolverine Blend — BPC-157 + TB-500 |
| Form | Lyophilised powder |
| BPC-157 content | 10mg |
| TB-500 content | 10mg |
| Total content | 20mg per vial |
| Purity | ≥98% (HPLC verified) |
| Grade | Research / analytical |
| Storage | −20°C, protected from light and moisture |
| Handling | Qualified laboratory professionals only |
Storage and Handling
To maintain compound stability and integrity:
Scientific References
Sikiric, P., et al. BPC-157 and molecular signalling in preclinical models. Current Pharmaceutical Design, 2018.
Chang, C.H., et al. BPC-157 effects on VEGF receptor pathway activation in vascular research. Journal of Physiology and Pharmacology, 2019.
Goldstein, A.L., et al. Thymosin Beta-4 and actin dynamics in cell migration research. Annals of the New York Academy of Sciences, 2012.
Philp, D., et al. TB-500 active domain and cytoskeletal regulation in in vitro models. FASEB Journal, 2004.
Ho, E.N., et al. Thymosin Beta-4 signalling and tissue modelling in preclinical studies. Expert Opinion on Biological Therapy, 2010.
Disclaimer
This product is supplied strictly for in vitro laboratory and scientific research use only (Research Use Only — RUO). It is not a pharmaceutical product, licensed medicine, dietary supplement, or medicinal device. It is not approved for, nor intended for, human or veterinary administration, consumption, or therapeutic application under any circumstances. The Wolverine Blend name is a community reference term used for product identification only and does not imply any therapeutic, performance, or health-related outcome. Researchers must comply with all applicable UK legislation, institutional biosafety requirements, and COSHH regulations when storing, handling, and disposing of this compound. Misuse of research-grade compounds outside of a regulated laboratory setting is solely the responsibility of the purchaser.
